These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 8634009)

  • 41. Gender differences in tardive dyskinesia: a critical review of the literature.
    Yassa R; Jeste DV
    Schizophr Bull; 1992; 18(4):701-15. PubMed ID: 1359633
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa.
    Patterson BD; Swingler D; Willows S
    Schizophr Res; 2005 Jul; 76(1):89-97. PubMed ID: 15927802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia.
    Tenback DE; van Harten PN; Slooff CJ; van Os J
    J Psychopharmacol; 2010 Jul; 24(7):1031-5. PubMed ID: 19487321
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tardive dyskinesia: a review.
    Latimer PR
    Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S49-54. PubMed ID: 8564917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biological determinants and risk factors for tardive dyskinesia in schizophrenia.
    Sandyk R
    Int J Neurosci; 1993; 69(1-4):35-51. PubMed ID: 7916008
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cognitive impairment in tardive dyskinesia.
    Wegner JT; Kane JM; Weinhold P; Woerner M; Kinon B; Lieberman J
    Psychiatry Res; 1985 Dec; 16(4):331-7. PubMed ID: 2868476
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics.
    Kinon BJ; Kollack-Walker S; Jeste D; Gupta S; Chen L; Case M; Chen J; Stauffer V
    J Geriatr Psychiatry Neurol; 2015 Mar; 28(1):67-79. PubMed ID: 25009161
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.
    Novick D; Haro JM; Bertsch J; Haddad PM
    J Clin Psychopharmacol; 2010 Oct; 30(5):531-40. PubMed ID: 20814320
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Naltrexone treatment of tardive dyskinesia in patients with schizophrenia.
    Wonodi I; Adami H; Sherr J; Avila M; Hong LE; Thaker GK
    J Clin Psychopharmacol; 2004 Aug; 24(4):441-5. PubMed ID: 15232337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. "Positive" and "negative" movement disorders in schizophrenia.
    Sandyk R; Kay SR
    Int J Neurosci; 1992 Oct; 66(3-4):143-51. PubMed ID: 1305614
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders.
    de Jesus Mari J; Lima MS; Costa AN; Alexandrino N; Rodrigues-Filho S; de Oliveira IR; Tollefson GD
    Eur Arch Psychiatry Clin Neurosci; 2004 Dec; 254(6):356-61. PubMed ID: 15538607
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The current status of tardive dyskinesia.
    Sachdev PS
    Aust N Z J Psychiatry; 2000 Jun; 34(3):355-69. PubMed ID: 10881961
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
    Margolese HC; Chouinard G; Kolivakis TT; Beauclair L; Miller R; Annable L
    Can J Psychiatry; 2005 Oct; 50(11):703-14. PubMed ID: 16363464
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tardive dyskinesia in the mentally retarded: comparison of prevalence, risk factors and topography with a schizophrenic population.
    Cohen S; Khan A; Zheng Y; Chiles J
    Acta Psychiatr Scand; 1991 Mar; 83(3):234-7. PubMed ID: 1674398
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study.
    Chan CH; Chan HY; Chen YC
    Int Clin Psychopharmacol; 2018 May; 33(3):155-162. PubMed ID: 29324468
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Handedness and the risk of tardive dyskinesia.
    Morgenstern H; Glazer WM; Doucette JT
    Biol Psychiatry; 1996 Jul; 40(1):35-42. PubMed ID: 8780853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Affective symptomatology in schizophrenia: a risk factor for tardive dyskinesia?
    Schulze TG; Müller DJ; Krauss H; Marwinski K; Maroldt AO; Novo Y Fernández A; Fimmers R; Held T; Maier W; Nöthen MM; Rietschel M
    Eur Psychiatry; 2001 Feb; 16(1):71-4. PubMed ID: 11246296
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial.
    Diehl A; Reinhard I; Schmitt A; Mann K; Gattaz WF
    Eur Psychiatry; 2009 Jan; 24(1):33-40. PubMed ID: 18774276
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tardive dyskinesia: neuropsychological, computerized tomographic, and psychiatric symptom findings.
    Gold JM; Egan MF; Kirch DG; Goldberg TE; Daniel DG; Bigelow LB; Wyatt RJ
    Biol Psychiatry; 1991 Sep; 30(6):587-99. PubMed ID: 1681948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.